TipRanks
Go Ultimate55% OFF

Legend Strategy International Holdings Group Co., Ltd. (1355) AI Stock Analysis

HK:1355

Legend Strategy International Holdings Group Co., Ltd.

(HKEX:1355)

Select Model
Rating:49Neutral
Price Target:HKD 0.24â–¼(-0.42% Downside)
Action:reiterated
Date:09/22/26

Overall score is held down primarily by very weak financial performance—multi-year losses, negative equity, and a 2025 shift to meaningful cash burn—despite supportive technical momentum with price trading above major moving averages. Valuation is also a drag because the company is loss-making (negative P/E) and offers no stated dividend yield.

Positive Factors
Revenue GrowthReported revenue growth provides evidence of continuing top-line demand and gives the company a base from which to improve operating performance. If sustained, this expansion can support better fixed-cost absorption and create opportunities to rebuild profitability over the next several quarters.
Negative Factors
Persistent Losses and Margin CompressionPersistent losses over four years, combined with an approximately -85% net margin in 2025, indicate that revenue is not currently translating into sustainable earnings. Sharp gross-margin compression further weakens the prospect of a near-term, self-funded recovery.

Legend Strategy International Holdings Group Co., Ltd. (1355) vs. iShares MSCI Hong Kong ETF (EWH)

-25%0%25%50%75%100%HK:1355+95.04%EWH+7.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
HKD 228.45M
Dividend Yield
―
Average Volume (3M)
1.39M
Price to Earnings (P/E)
-16.9
Beta (1Y)
0.75
Revenue Growth
8.34%
EPS Growth
80.94%
Country
Hong Kong
Employees
94
Sector
Consumer Cyclical
Sector Strength
61
Industry
Travel Lodging

Legend Strategy International Holdings Group Co., Ltd. Business Overview & Revenue Model

Company Description

Legend Strategy International Holdings Group Company Limited, an investment holding company, engages in the accommodation operation and consultancy business in the People’s Republic of China. It also provides property facilities management, franchise...

Legend Strategy International Holdings Group Co., Ltd. Financial Statement Overview

Summary

Financials are highly strained: profitability has deteriorated into persistent, deep losses (2022–2025) with very weak 2025 margins (~-85% net margin and sharply lower gross margin). The balance sheet is a major risk with negative shareholders’ equity (2023–2025) and very high effective leverage. Cash flow was supportive in 2021–2024, but 2025 turned sharply negative, increasing near-term funding pressure.

Income Statement

18Very Negative

Balance Sheet

8Very Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue50.95M51.30M40.68M67.66M63.00M70.56M
Gross Profit-1.44M1.11M21.67M45.35M6.88M15.63M
EBITDA-23.00M-20.66M25.66M-23.72M21.91M38.05M
Net Income-8.90M-43.53M-21.12M-38.18M-7.79M4.98M
Balance Sheet
Total Assets71.51M80.44M75.05M127.32M196.17M240.18M
Cash, Cash Equivalents and Short-Term Investments1.09M2.44M13.86M4.26M6.35M17.05M
Total Debt101.91M162.19M164.99M181.60M175.86M203.62M
Total Liabilities124.37M183.34M180.40M210.06M217.04M242.16M
Stockholders Equity-14.39M-35.25M-42.35M-36.35M2.18M12.32M
Cash Flow
Free Cash Flow-11.50M-49.60M24.01M34.51M6.41M14.06M
Operating Cash Flow-4.72M-32.69M24.27M35.16M9.35M30.40M
Investing Cash Flow-29.05M-29.64M-250.00K-644.00K-2.93M-16.31M
Financing Cash Flow22.89M50.81M-11.98M-34.94M-19.01M-19.81M

Legend Strategy International Holdings Group Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price0.24

Price Trends

50DMA0.19Positive
100DMA0.16Positive
200DMA0.14Positive

Market Momentum

MACD0.01Negative
RSI69.62Neutral
STOCH108.79Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1355, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.19, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 69.62 is Neutral, neither overbought nor oversold. The STOCH value of 108.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1355.

Legend Strategy International Holdings Group Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

HK:1355 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1221HK:122172OutperformHKD 1.70B17.302.28%2.11%3.53%-7.42%
HK:0184HK:018468NeutralHKD 768.85M2.548.45%5.53%6.80%67.22%
HK:0201HK:020162NeutralHKD 608.40M16.190.90%―6.29%―
Sector *61Neutral$18.38B12.79-2.54%3.03%1.52%-15.83%
HK:1355HK:135549NeutralHKD 422.35M-16.8635.86%―8.34%80.94%
HK:0617HK:061749NeutralHKD 205.08M-0.25-10.26%―63.78%49.79%
HK:0078HK:007838UnderperformHKD 337.04M-0.69-6.04%―49.29%79.61%

* Consumer Cyclical Sector Average

Performance Comparison

0%50%100%HK:1355HK:0184HK:0201HK:1221HK:0617HK:0078Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
HK:1355 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:1355Legend Strategy International Holdings Group Co., Ltd.0.240.13129.13%
HK:0184Keck Seng Investments (Hong Kong) 2.260.125.56%
HK:0201Magnificent Hotel Investments Limited0.07-0.00-2.86%
HK:1221Sino Hotels (Holdings) Ltd.1.420.010.57%
HK:0617Paliburg Holdings Limited0.18-0.09-31.85%
HK:0078Regal Hotels International Holdings Limited0.38-0.22-37.50%

Legend Strategy International Holdings Group Co., Ltd. Corporate Events

Biosysen Sets Dilution Protections on HK$50 Million Convertible Bonds

Sep 22, 2026

Biosysen Limited, formerly known as Legend Strategy International Holdings Group Co., Ltd., is a Cayman Islands–incorporated company listed in Hong Kong that uses convertible bonds as part of its financing strategy. Its HK$50 million bond issue...

Biosysen Raises HK$39 Million Through Fully Placed Rights Issue to Fund R&D

Sep 7, 2026

Biosysen Limited, formerly Legend Strategy International Holdings Group Co., Ltd., is a Hong Kong-listed company incorporated in the Cayman Islands and currently emphasizing research and development initiatives. The firm plans to deploy new capital m...

Biosysen Limited Publishes Unaudited Interim Results for First Half of 2026

Aug 31, 2026

Biosysen Limited has released its unaudited condensed consolidated interim results for the six months ended 30 June 2026, prepared in line with Hong Kong Stock Exchange listing rules. The interim report, reviewed by the board’s audit committee,...

Biosysen Rights Issue Undersubscribed; Unplaced Shares to Be Marketed via Compensatory Placing

Aug 25, 2026

Biosysen Limited has reported the results of its rights issue, launched on the basis of one rights share for every two existing shares at a subscription price of HK$0.068 per share. The offer comprised 596,532,580 rights shares, all available to qual...

Biosysen forecasts swing to profit on lease-termination gain

Aug 24, 2026

Biosysen Limited has issued a positive profit alert indicating that it expects to swing to a net profit of about HK$20 million for the six months ended 30 June 2026, compared with a loss of approximately HK$13.5 million a year earlier. The improvemen...

Biosysen Sets Board Meeting to Review Interim Results and Potential Dividend

Aug 19, 2026

Biosysen Limited has scheduled a board meeting for 31 August 2026 to review and approve the unaudited interim results of the company and its subsidiaries for the six months ended 30 June 2026. The meeting will also consider a possible recommendation...

Biosysen Completes HK$50 Million Convertible Bond Issue, Paving Way for Ownership Shift

Aug 5, 2026

Biosysen Limited has completed the issuance of HK$50 million in convertible bonds to a major shareholder-linked subscriber, with the subscription price settled through a set-off against an existing loan, fully discharging the company’s repaymen...

Biosysen Seeks Fivefold Increase in Authorised Share Capital to Support Growth

Aug 5, 2026

Biosysen Limited has proposed increasing its authorised share capital from HK$20 million to HK$100 million, raising the number of authorised shares from 2 billion to 10 billion. The additional 8 billion shares, if issued, will rank pari passu with ex...

Biosysen Seeks Fivefold Increase in Authorised Share Capital Ahead of August EGM

Aug 4, 2026

Biosysen Limited has called an extraordinary general meeting to seek shareholder approval for a substantial increase in its authorised share capital from HK$20 million to HK$100 million, raising the number of shares from 2 billion to 10 billion. The...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 22, 2026